HK1246641A1 - 緩釋性醫藥組合物 - Google Patents
緩釋性醫藥組合物Info
- Publication number
- HK1246641A1 HK1246641A1 HK18106001.4A HK18106001A HK1246641A1 HK 1246641 A1 HK1246641 A1 HK 1246641A1 HK 18106001 A HK18106001 A HK 18106001A HK 1246641 A1 HK1246641 A1 HK 1246641A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sustained
- pharmaceutical composition
- release pharmaceutical
- release
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055196 | 2015-03-18 | ||
| PCT/JP2016/058455 WO2016148228A1 (ja) | 2015-03-18 | 2016-03-17 | 徐放性医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246641A1 true HK1246641A1 (zh) | 2018-09-14 |
Family
ID=56919076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104433.7A HK1245083A1 (zh) | 2015-03-18 | 2018-04-03 | 緩釋性醫藥組合物 |
| HK18106001.4A HK1246641A1 (zh) | 2015-03-18 | 2018-05-09 | 緩釋性醫藥組合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104433.7A HK1245083A1 (zh) | 2015-03-18 | 2018-04-03 | 緩釋性醫藥組合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11090296B2 (zh) |
| EP (1) | EP3272362B1 (zh) |
| JP (2) | JP2016175900A (zh) |
| KR (2) | KR20170129170A (zh) |
| CN (1) | CN107427587A (zh) |
| AR (1) | AR105947A1 (zh) |
| CA (1) | CA2979971A1 (zh) |
| ES (1) | ES2969514T3 (zh) |
| HK (2) | HK1245083A1 (zh) |
| RU (1) | RU2704813C2 (zh) |
| TW (1) | TWI731853B (zh) |
| WO (1) | WO2016148228A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2979971A1 (en) * | 2015-03-18 | 2016-09-22 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
| CA2972296A1 (en) * | 2016-06-30 | 2017-12-30 | Durect Corporation | Depot formulations |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| KR20210003877A (ko) | 2018-05-01 | 2021-01-12 | 치비 인코포레이티드 | 약제를 눈에 비침습적으로 지속 전달하기 위한 액체 데포 |
| AU2019262061A1 (en) * | 2018-05-01 | 2020-11-26 | Chibi, Inc. | Eye drop formulation and method for sustained delivery of medicament to the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001388A (en) * | 1973-06-14 | 1977-01-04 | Alza Corporation | Ophthalmological bioerodible drug dispensing formulation |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| WO2005085201A1 (ja) | 2004-02-17 | 2005-09-15 | Santen Pharmaceutical Co., Ltd. | 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物 |
| CN101060831B (zh) * | 2004-10-01 | 2010-06-23 | 拉姆斯科股份有限公司 | 可方便植入的缓释药物组合物 |
| AU2005294382A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| AU2006213673A1 (en) * | 2005-02-09 | 2006-08-17 | Santen Pharmaceutical Co., Ltd. | Formulations for ocular treatment |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2008143992A2 (en) | 2007-05-18 | 2008-11-27 | Durect Corporation | Improved depot formulations |
| KR20100055482A (ko) | 2007-08-16 | 2010-05-26 | 마커사이트, 인코포레이티드 | 안질환 또는 안이상의 치료를 위한 제제 |
| BR112012001159A2 (pt) | 2009-07-17 | 2016-03-01 | Santen Pharmaceutical Co Ltd | benzenossulfonato de 2 - [[[2 -[(hidroxiacetil) amino]- 4 -piridinil] metil] tio]- n -[4 - (trifluorometóxi) fenil]- 3 - piridinacarboxamida, cristal do mesmo, cristal polimorfo do mesmo, e métodos para produção do mesmo |
| PT2717914T (pt) | 2011-06-10 | 2019-12-18 | Ramscor Inc | Formulações de libertação sustentada para administração de proteínas ao olho e métodos de preparação das mesmas |
| CA2869377C (en) | 2012-04-09 | 2022-11-08 | Scidose, Llc | Fulvestrant formulations |
| JP5856264B2 (ja) | 2013-09-20 | 2016-02-09 | 参天製薬株式会社 | ポリエチレングリコール含有組成物 |
| JP2016104708A (ja) * | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| CA2979971A1 (en) * | 2015-03-18 | 2016-09-22 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
| US10682340B2 (en) * | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| CA2972296A1 (en) * | 2016-06-30 | 2017-12-30 | Durect Corporation | Depot formulations |
-
2016
- 2016-03-17 CA CA2979971A patent/CA2979971A1/en active Pending
- 2016-03-17 JP JP2016053405A patent/JP2016175900A/ja active Pending
- 2016-03-17 RU RU2017134354A patent/RU2704813C2/ru active
- 2016-03-17 EP EP16765057.1A patent/EP3272362B1/en active Active
- 2016-03-17 KR KR1020177027688A patent/KR20170129170A/ko not_active Application Discontinuation
- 2016-03-17 ES ES16765057T patent/ES2969514T3/es active Active
- 2016-03-17 CN CN201680015702.4A patent/CN107427587A/zh active Pending
- 2016-03-17 WO PCT/JP2016/058455 patent/WO2016148228A1/ja active Application Filing
- 2016-03-17 US US15/558,260 patent/US11090296B2/en active Active
- 2016-03-17 AR ARP160100718A patent/AR105947A1/es unknown
- 2016-03-17 TW TW105108258A patent/TWI731853B/zh active
- 2016-03-17 KR KR1020237021936A patent/KR20230104762A/ko not_active Application Discontinuation
-
2018
- 2018-04-03 HK HK18104433.7A patent/HK1245083A1/zh unknown
- 2018-05-09 HK HK18106001.4A patent/HK1246641A1/zh unknown
-
2020
- 2020-04-02 JP JP2020066353A patent/JP6955604B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI731853B (zh) | 2021-07-01 |
| JP2016175900A (ja) | 2016-10-06 |
| RU2017134354A (ru) | 2019-04-03 |
| US11090296B2 (en) | 2021-08-17 |
| TW201639569A (zh) | 2016-11-16 |
| JP2020117522A (ja) | 2020-08-06 |
| EP3272362B1 (en) | 2023-12-13 |
| JP6955604B2 (ja) | 2021-10-27 |
| KR20230104762A (ko) | 2023-07-10 |
| RU2017134354A3 (zh) | 2019-04-19 |
| KR20170129170A (ko) | 2017-11-24 |
| RU2704813C2 (ru) | 2019-10-31 |
| WO2016148228A1 (ja) | 2016-09-22 |
| EP3272362A4 (en) | 2018-12-05 |
| HK1245083A1 (zh) | 2018-08-24 |
| EP3272362A1 (en) | 2018-01-24 |
| AR105947A1 (es) | 2017-11-29 |
| US20180042907A1 (en) | 2018-02-15 |
| CA2979971A1 (en) | 2016-09-22 |
| CN107427587A (zh) | 2017-12-01 |
| ES2969514T3 (es) | 2024-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265360B (en) | Pharmaceutical composition | |
| IL265260B (en) | pharmaceutical preparations | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| GB201517217D0 (en) | Pharmaceutical compounds | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| GB201517216D0 (en) | Pharmaceutical compounds | |
| IL262654A (en) | Pharmacy preparation | |
| IL265349A (en) | Pharmaceutical composition | |
| HK1246641A1 (zh) | 緩釋性醫藥組合物 | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| HK1245073A1 (zh) | 藥物組合物 | |
| PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
| GB201615917D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| RS61548B1 (sr) | Farmaceutski sastav sa produženim oslobađanjem koji sadrži rivastigmin | |
| GB201615910D0 (en) | Pharmaceutical composition | |
| GB201615914D0 (en) | Pharmaceutical composition | |
| IL265436B (en) | Pharmacy preparation | |
| HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
| IL265428A (en) | Pharmaceutical composition |